Galderma Group N Cash Flow Conversion Efficiency

Latest as of June 2025: 0.061x

Galderma Group N cash flow conversion efficiency. Based on the latest financial reports, Galderma Group N (GALD) has a cash flow conversion efficiency ratio of 0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF475.06 Million ≈ $600.61 Million USD) by net assets (CHF7.73 Billion ≈ $9.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Galderma Group N worth for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Galderma Group N (2021–2024)

Cash flow conversion efficiency of Galderma Group N from 2021 to 2024. This chart illustrates how Galderma Group N's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GALD live share price for real-time trading data and today's change.

Galderma Group N Cash Flow Conversion Ratio Explained

Galderma Group N cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Galderma Group N Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Galderma Group N ranked by their cash flow conversion efficiency. Review Galderma Group N free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Public Service Enterprise Group Inc NYSE:PEG	0.041x
PTT Public Company Limited BK:PTT	0.031x
Lonza Group AG SW:LONN	0.081x
KOMATSU LTD. SPONS. ADR 1 F:KOMA	N/A
KB Financial Group KO:105560	0.025x
PT BK CE.AS.ADR/25 RP625 F:BZG	0.041x
Mahindra & Mahindra Limited NSE:M&M	0.000x
China CSSC Holdings Ltd SHG:600150	0.014x

Annual Cash Flow Conversion Efficiency for Galderma Group N (2021–2024)

The table below shows the annual cash flow conversion efficiency of Galderma Group N from 2021 to 2024. Also see Galderma Group N assets under control for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF7.79 Billion ≈ $9.85 Billion	CHF429.77 Million ≈ $543.34 Million	0.055x	+67.62%
2023-12-31	CHF4.52 Billion ≈ $5.71 Billion	CHF148.64 Million ≈ $187.92 Million	0.033x	+28.01%
2022-12-31	CHF4.13 Billion ≈ $5.23 Billion	CHF106.30 Million ≈ $134.39 Million	0.026x	-40.45%
2021-12-31	CHF4.14 Billion ≈ $5.24 Billion	CHF178.92 Million ≈ $226.21 Million	0.043x	--

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$57.25 Billion

CHF45.29 Billion CHF

Market Cap Rank

#728 Global

#12 in Switzerland

Share Price

CHF192.85

Change (1 day)

+1.66%

52-Week Range

CHF142.10 - CHF192.85

All Time High

CHF192.85